Most patients in HR positive group accepted five years of treatment with tamoxifen or an aromatase inhibitor, which provides a significant survival benefits in patients with early-stage breast cancer [33] and reduces the risk of new contralateral breast tumors [34–35]. This evidence concerns the gene CYP19A1 and breast cancer.